Get startedLog in
    Picture of ORYZON Genomics SA logo

    ORY — ORYZON Genomics SA News Story

    0.000.00%
    es flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapSucker Stock
    All News

    Brief: Oryzon Gets U.S. Patent Allowance For Iadademstat And Gilteritinib Drug Combo Application

    Picture of ORYZON Genomics SA logoORYZON Genomics SA
    31/08/2026 07:16
    BRIEF-Oryzon Gets U.S. Patent Allowance For Iadademstat And Gilteritinib Drug Combo Application
    Aug 31 (Reuters) - Oryzon Genomics SA ORY.MC:
    • ANNOUNCES NOTICE OF ALLOWANCE FOR U.S. PATENT APPLICATION COVERING IADADEMSTAT COMBINATION WITH GILTERITINIB
    • U.S. PATENT EXPECTED TO EXPIRE IN 2042
    Source text
    Further company coverage: ORY.MC

    (Gdansk Newsroom)
    ((gdansk.newsroom@thomsonreuters.com; +48 567 69 66 00;))

    Recent news on ORYZON Genomics SA

    See all news